With over 30 years in the life science and pharma industries and deep roots in respiratory, ISAB’s new Board member Jan Hellqvist has extensive experience growing SMEs to…
On 24 May Inhalation Sciences AB presented a major strategy update on its plans and goals for growth at RedEye in Stockholm Sweden. Watch the full presentation, by…
Sign up for the up-coming webinar with Snezana Radivojev, Dr. Scient. Med. from the RCPE institute in Graz, Austria, on 27 April 2022, at 4:00 PM CET (10:00…
Inhalation Sciences will be represented at SOT by TSE systems. Please visit booth #629 and talk to Thomas Budiman and Daniela Oettler to learn more about PreciseInhale® and…
ISAB CEO Manoush Masarrat interviewed on ISAB’s strong Q4 sales, PreciseInhale’s positive clinical results and the year ahead.
Follow Inhalation Sciences investor relations activities in the first half of 2022
At the end of October Inhalation Sciences presented the PreciseInhale® system and how it can be used to generate highly valuable data in the early inhalation generic development….
On 19-20 May ISAB digitally trained the lab team at Aquilon Pharma to remotely install and operate its new PreciseInhale® system, the third such remote installation and training…
AQUILON PHARMA PURCHASES PRECISEINHALE FOR INNOVATIVE ASTHMA AND COPD RESEARCH Aquilon Pharma, based in Belgium, has purchased ISAB’s high-precision R&D system PreciseInhale®, plus its Nose-Only and Intratracheal Exposure Modules,…
NEW PUBLICATION, NEW SALES, NEW JOINT DEVELOPMENT PROJECT: News roundup for Fall 2020 for Inhalation Sciences ISAB & ASTRAZENECA: LANDMARK PAPER ON PRECISEINHALE® IN LARGE ANIMALS RELEASED Inhalation…
